Inozyme Pharma Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 38
Employees
  • Stock Symbol
  • INZY
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $9.25
  • (As of Friday Closing)

Inozyme Pharma General Information

Description

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Contact Information

Website
www.inozyme.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 321 Summer Street
  • Suite 400
  • Boston, MA 02210
  • United States
+1 (857) 000-0000

Inozyme Pharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inozyme Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.25 $9.45 $9.01 - $29.46 $219M 23.7M 94.3K -$1.10

Inozyme Pharma Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 258,932 322,914
Revenue 0 0 0 0
EBITDA (63,010) (56,577) (20,747) (7,222)
Net Income (62,803) (56,424) (19,724) (6,964)
Total Assets 148,259 169,363 47,944 43,543
Total Debt 3,704 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Inozyme Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inozyme Pharma‘s full profile, request access.

Request a free trial

Inozyme Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Inozyme Pharma‘s full profile, request access.

Request a free trial

Inozyme Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseas
Drug Discovery
Boston, MA
38 As of 2020
00000
0000 0000-00-00
00000000 00000

000000 0

uis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000 000000000
Burlingame, CA
00 As of 0000
00000
000000 - 000 00000

0000000

ehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cu
0000000000000
New York, NY
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inozyme Pharma Competitors (76)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 000000 Formerly VC-backed New York, NY 000 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
You’re viewing 5 of 76 competitors. Get the full list »

Inozyme Pharma Patents

Inozyme Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200263153-A1 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Pending 27-Sep-2017 00000000
CA-3096821-A1 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Pending 27-Sep-2017 000000000
JP-2020535161-A A method for improving cardiovascular function and treating cardiovascular disease using recombinant ectnucleotide pyrophosphatase / phosphodiesterase (npp1). Pending 27-Sep-2017 00000000
EP-3687565-A1 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Pending 27-Sep-2017 C12N9/16

Inozyme Pharma Executive Team (13)

Name Title Board Seat Contact Info
Axel Bolte Chief Executive Officer & Founder
Henric Bjarke Chief Operating Officer, Operations & Senior Vice President
Yves Sabbagh Ph.D Chief Scientific Officer & Senior Vice President
Steven Jungles Executive & Senior Vice President
Demetrios Braddock Ph.D Scientific Founder, Chairperson of Scientific Advisory Board and Board Observer
You’re viewing 5 of 13 executive team members. Get the full list »

Inozyme Pharma Board Members (10)

Name Representing Role Since
Demetrios Braddock Ph.D Inozyme Pharma Scientific Founder, Chairperson of Scientific Advisory Board and Board Observer 000 0000
Douglas Treco Ph.D Inozyme Pharma Chairman & Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
Lynne Sullivan Self Board Member 000 0000
Martin Edwards MD Novo Holdings Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Inozyme Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inozyme Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inozyme Pharma‘s full profile, request access.

Request a free trial

Inozyme Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 17-Jul-2020 000000000 00000 00 Buildings and Property 0000 00000
To view Inozyme Pharma’s complete investments history, request access »